Streetwise
Lauren Rudd
Sunday, January 12, 2014
Put Wall Street in Proper Perspective
If you are going to invest on Wall Street, please be
cognizant of the fact that there is no proven relationship between historical
and future corporate share prices. The past will not predict the future unless
you have the exact same initial conditions, which is impossible.
Does that mean you ignore historical data? No, you simply
need to put the data in proper perspective. It is possible to ascertain, with a
degree of assuredness, certain price pattern characteristics from which you can
deduce with a degree of confidence the likelihood of a price movement in a
specific direction.
Wait a second; didn’t you just say that the past cannot
predict the future and that there is no relationship between historical and
future stock prices? Yes, but you are not predicting the future. What you are
doing is analyzing the one thing that investment prices have in common...that
they are a reflection of the hopes, fears, optimism and greed of the market’s
participants.
The sum total of those emotions is what directs a stock’s
share price. In other words, what you are seeing is supply and demand reaching
continually changing states of equilibrium. More specifically, I have it, you
want it and so we agree upon a price and a transaction takes place. It is as
simple as that and it happens thousands of times each day.
As Garfield Drew noted in his book, “New Methods for Profit
in the Stock Market,” the quoted price of a stock is never what the stock is
worth but rather what people think it is worth.
Martin Pring wrote in his book, “Technical Analysis
Explained,” the price of a share of stock is a reflection of the changes in
investor attitude, while time measures recurrence of those changes and volume is
essentially a measure of the intensity of those changes. I would not argue with
that.
Because the price patterns of stock prices have been
repeatedly analyzed and catalogued, technical analysis distills down to a degree
of self-fulfilling prophecy. If everyone believes a pattern means an investment
vehicle’s price will rise, the upshot is an upward price move.
Therefore, your objective, via technical analysis, is to
analyze the mood of the crowd and then take either a similar or a contrarian
position. Unfortunately, whenever the price of a security draws an inordinate
amount of attention there is also a tendency to lean on boisterous
prognosticators for advice. That is a mistake. Never take the opinions you hear
or read to be the gospel.
Continuing with that line of reasoning, no matter how
“in-favor” or “out-of-favor” a particular investment is never let anyone
pressure you into a knee-jerk reaction. A person selling an investment is
unequivocally biased. It does not matter how many letters they have after their
name, how sincere they appear, or how long you have known them; they sell for a
living. Always obtain an independent second opinion, preferably from your own
research.
Yes, virtually everyone can learn to undertake at least a
minimal amount of investment research. A good place to start might be MWI
Veterinary Supply (MWIV). It is one of the companies I mentioned in my list last
week. The company is a leading distributor of animal health products.
When I wrote about MWI a year ago, my earnings estimate for
fiscal year ended September 30, was $4.75 per share with a 12-month price target
of $128. So how did the company do? Earnings for the year came in at $4.95 and
the shares recently closed at $175.33.
MWI’s guidance is for FY 2015 revenues of $2.89 to $2.94
billion, representing a growth rate of 23 to 25 percent, while earnings are
projected at $5.47 to $5.67 per share, an increase of 10.5 to 14.5 percent
year-over-year.
The intrinsic value using the discounted earnings model with an earnings growth
rate of 16 percent and a discount rate of 12 percent is $183 per share, while
the more conservative free cash flow to the firm model with a revenue growth
rate of 19 percent yields an intrinsic value of $199 per share. My earnings
estimate for this year is $5.74 per share, with a 12-month price target of $196
for a 12 percent capital gain.